Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. (NASDAQ: LAB) is an analytical laboratory instrument manufacturer focused on technologies that help biomedical researchers develop better medicines faster. Company news frequently highlights its standardized next-generation platforms, including SomaScan, mass cytometry and microfluidics technologies, which are used to generate reliable and repeatable insights into health and disease for translational and clinical research.
News updates for LAB commonly cover financial results and outlook, such as quarterly earnings releases and preliminary revenue announcements. These disclosures provide detail on revenue from continuing operations, trends across consumables, instruments and services, and the company’s progress toward its stated profitability goals, often accompanied by commentary on restructuring plans and cost-saving initiatives.
Another important news theme is strategic transactions and partnerships. Standard BioTools has announced a Stock Purchase Agreement with Illumina, Inc. under which Illumina will acquire SomaLogic and related assets, while Standard BioTools retains its mass cytometry and microfluidics businesses. Press releases also describe collaborations, such as work with Molecular Instruments to integrate HCR imaging technologies with the Hyperion Imaging System for next-generation Imaging Mass Cytometry workflows, and the selection of the SomaScan 11K Assay by the PRECISE-SG100K biobank for large-scale population health research.
Visitors to this LAB news page can review these company-issued updates, including information on operational restructuring, facility consolidation, workforce changes, and large biobank and population proteomics projects. Monitoring this stream of announcements can help investors and researchers understand how Standard BioTools is evolving its portfolio, managing its cost structure, and participating in the broader life sciences and multiomics ecosystem.
Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue results for Q4 and the full year 2024.
For Q4, the company expects revenue of approximately $46.5 million, contributing to a full-year revenue of around $174 million. This meets the top end of their revised guidance, adjusted in Q2 to account for industry-wide challenges.
CEO Michael Egholm highlighted significant progress in reducing operating expenses through the implementation of Standard BioTools Business Systems (SBS). He emphasized the need for continued discipline and improvement. Looking ahead to 2025, the company aims to achieve further efficiencies from integration, enhancing their R&D and shifting revenues towards high-margin offerings.
Egholm expressed optimism about the company's strategy and team, aiming for long-term value for shareholders and customers. The company will report detailed financial results for Q4 and the full year 2024 later this quarter, along with their 2025 outlook.
The preliminary results are subject to completion of annual audit procedures and internal reviews.
Standard BioTools (NASDAQ: LAB) announced that its SomaScan Platform was instrumental in a Nature Medicine study examining semaglutide's effects on obesity treatment. The research, conducted by Novo Nordisk, analyzed approximately 6,400 human proteins across nearly 2,000 participants from two phase 3 trials.
The study revealed significant changes in protein biomarkers linked to metabolic pathways, providing new insights into semaglutide's biological mechanisms and potential broader health benefits. The SomaScan Technology demonstrated unique advantages, including mechanistic insights into proteins and pathways, reliable results across studies, and the potential to accelerate clinical development through a validated 27-protein predictor that detected cardiovascular benefits in smaller, shorter studies.
Standard BioTools (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will be held from January 13th to 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s presentation is scheduled for January 16th, 2024, at 9:45 a.m. PT. A live audio webcast of the presentation will be accessible via the Investor Relations page on the company’s website. An archived recording will also be available for later access on the same page.
Standard BioTools (Nasdaq: LAB) has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and former Chief Operating Officer of Standard BioTools, brings nearly 30 years of healthcare and life sciences industry experience. Previously, he served as President of Milliken's Healthcare Division and held leadership positions at Pall and Danaher Throughout his career, Kim has completed over 40 transactions in healthcare, medical technology, and life sciences sectors. Concurrent with Kim's appointment, Jonathan Mickelsen has been promoted to Vice President & Chief Accounting Officer.
Standard BioTools (NASDAQ: LAB) has announced its management team's participation in two major investor conferences in November 2024. President and CEO Michael Egholm, PhD, will deliver corporate presentations at the UBS Global Healthcare Conference on November 12 at 1:15 p.m. PT and at the Jefferies London Healthcare Conference on November 19 at 8:30 a.m. GMT. The presentations will be webcast live on the company's Investor Relations page, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported Q3 2024 revenue of $45 million, down 5% year-over-year. The company achieved a 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year. Key financial metrics include: consumables revenue up 13%, instruments revenue down 42%, and services revenue flat. The company maintains $368 million in cash and investments. Operating expenses decreased 18.5% to $55 million, while net loss improved to $26.9 million. The company has operationalized $80 million in merger synergies, expected to be fully realized in 2025, and reaffirmed FY2024 revenue guidance of $170-175 million.
Standard BioTools Inc. (NASDAQ: LAB) has announced its plans to report third quarter 2024 financial results on Wednesday, October 30, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET on the same day to discuss the results and operational progress.
Interested individuals can join the call by dialing (888) 346-3970 for US domestic callers or (412) 902-4297 for international callers. A live audio webcast will be available on the company's Investor Relations page. The webcast will be archived for future access on Standard BioTools' Investor Relations page at investors.standardbio.com.
Standard BioTools Inc. (Nasdaq:LAB) has announced an expansion of its SomaScan® 11K Platform, now including protein measurements on a broader range of sample types such as cerebrospinal fluid (CSF), aqueous humor, tissue homogenates, and cell lysates. This platform provides 11,000 protein measurements simultaneously from sample volumes as low as 55 µl, covering half of the human proteome in a single assay.
The expansion supports translational medicine by advancing research in disease causation, clinical pharmacology, and drug development. The platform's high precision, with a median coefficient of variation around 5%, offers more statistical power for discoveries. This update is particularly beneficial for oncology and neurology research, allowing matched samples to plasma in various sample types.
Services for these new sample types are available from Standard BioTools' CAP/CLIA-certified Services Lab in Boulder, Colorado, and from SomaScan® Authorized Sites globally.
Standard BioTools Inc. (Nasdaq:LAB) announced a study published in Nature Scientific Reports that utilized their SomaScan® Assay and SomaSignal™ tests to analyze blood serum samples from patients in a Phase 2a clinical trial for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The study identified 69 blood biomarkers correlating with clinical measures of liver disease.
Researchers used the 7,000-protein biomarker panel to infer liver biopsy effects and identify additional mechanistic pharmacodynamic protein biomarkers. The SomaSignal tests helped stratify patients by disease severity, establish pre-treatment baselines, and monitor drug effects. The study demonstrated the utility of these tests for NASH classification and treatment-induced effects on steatosis.